Acizo LS is a combination of rabeprazole and levosulpiride.
It is a proton pump inhibitor which inhibits the secretion of gastric acid. It belongs to the same class as that of omeprazole.
It is a benzamide class of antipsychotic drug. It is mainly used for the treatment of psychosis and major depressive disorder. Levosulpiride is levo-isomer.
- Short term treatment for erosion of stomach
- Ulceration of esophagus caused by GERD
- Maintenance therapy for long term use after initial response
- In treatment with H. pylori infections
- Chronic gastritis
- Irritable bowel disease
- Healing of duodenal ulcer
25-200 mg/day in divided doses
It is PPI which suppresses the gastric acid production. It acts by suppressing the final step in gastric acid formation. It produces dose related response.
It acts as D2 receptor antagonist. It is a moderate antagonist at 5HT receptor. This property enhances its therapeutics efficacy in gastrointestinal disorder. This property with D2 receptor antagonism contributes its GI pk effect.
After oral administration it is well absorbed in the body.
The drug is metabolized by the liver with Cmax about 2.5mcg/ml. the peak concentration of the drug is about 2.5hrs. The apparent volume of distribution is 11.0-23.6 L.
About 18% of the drug is excreted in feces through biliary excretion.
It is well absorbed in the body with oral bioavailability about 30% with peak plasma concentration achieving in 3hrs.
The drug is excreted through urine with plasma half life 4.3hr.
- The drug overdose cannot be removed
- Limb splay
- Lateral position
- Absence of ear reflex
- Hypersensitivity to the formulation ingredient
- Pregnant and breast feeding mothers
- Atrophic gastritis
- Acute intestinal nephritis
- Long treatment with acid suppressants can cause cyanocobalamin deficiency
- Clostridium difficile associated diarrhea
- Increased risk of osteoporosis